AstraZeneca Acknowledges Rare Side Effects of COVID Vaccine in Ongoing Legal Battle

AstraZeneca, the pharmaceutical company behind the Oxford–AstraZeneca Covid vaccine, has made a significant admission in court regarding the potential rare side effects of its vaccine. Sold globally under brand names like Covishield and Vaxzevria, the vaccine was developed in collaboration with the University of Oxford.

The admission comes amidst an ongoing class-action lawsuit filed against AstraZeneca, where families are alleging serious injuries and deaths as a result of the vaccine. The lawsuit was initiated by Jamie Scott, who suffered a permanent brain injury post receiving the vaccine in April 2021.

The specific rare side effect under scrutiny is Thrombosis with Thrombocytopenia Syndrome (TTS), characterized by blood clotting and low platelet counts. AstraZeneca, in court documents submitted to the UK High Court, acknowledged that its vaccine ‘can, in very rare cases, cause TTS.’ This admission signifies a crucial moment in the legal battle, shedding light on the potential risks tied to vaccination.

Despite conceding the link to TTS, AstraZeneca refutes claims of widespread defects in the vaccine or exaggeration of its efficacy. The legal disputes are ongoing, and potential payouts may follow if the company recognizes vaccine-induced illnesses or fatalities in specific cases.